Dr. David Hennings is the Vice President of CMC for Sudo Biosciences. Prior to Sudo, he was Vice President of CMC for Cortexyme, a pharmaceutical company developing novel treatments for neurodegenerative diseases, where he was responsible for the development and delivery of drug substance and drug product to support the company’s lead candidate in clinical trials. Dr. Hennings served in positions of increasing responsibility over a 14-year tenure at Array Biopharma (acquired by Pfizer), where he established interdisciplinary CMC teams to manage the development of multiple programs in oncology as well as other therapeutic areas such as antibacterial products and pain/inflammation in oncology.

At Array, he was senior team leader for projects including Varlitinib (ARRY-543) and a p38 inhibitor (ARRY-797), and also led the spin-out of the Array CMC group to form Avista Pharma Solutions. Dr. Hennings was also Senior Director of Business Development and Head of US Sales at STA Pharmaceutical, a WuXi AppTec company. He started his career at Bristol-Myers Squibb after completing his post-doc training at Colorado State University. He obtained a B.S. in Chemistry from Northeast Missouri State and a Ph.D. in Organic Chemistry from the University of Chicago.